Olaparib for Ovarian Cancer: 12 Real Stories

Ovarian Cancer: Robyn's Survivor Story

Patient Info: Robyn Townsend

After surgery, 6 rounds of chemotherapy and ongoing olaparib, she reported no evidence of disease since the previous December.

MD AndersonRead more →

Ovarian Cancer Remission With Olaparib After Chemotherapy Intolerance

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: germline BRCA1 mutation

At 48 months, imaging showed complete remission and CA125 was normal while she continued reduced-dose olaparib.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Evelyn's Survivor Story

Patient Info: Evelyn, female | Stage IV

Biomarkers: HRD-positive

After chemotherapy and surgery, Evelyn reported an unremarkable final scan in May 2023 and then completed 2 years of Lynparza maintenance therapy guided by HRD-positive tumor testing.

Stage III BRCA1 Ovarian Cancer: Carla's Survivor Story

Patient Info: Carla Peoples, female | Stage III

Biomarkers: BRCA1 mutation

She was cancer-free after surgery and 6 rounds of chemotherapy and continued olaparib maintenance with CA-125 blood testing every 3 weeks.

MD AndersonRead more →

Ovarian Cancer Spreads to the Breast During Platinum-Resistant Recurrence

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2-negative; HRD-positive; PD-L1-positive; folate receptor alpha-positive

Metastatic Site: right breast, right axillary lymph nodes, cervical…

She remained alive with stable disease about 2 years after the breast metastasis was diagnosed while receiving seventh-line mirvetuximab-soravtansine.

PubMed CentralRead more →

Stage IIIC Ovarian Cancer Found During Preoperative Screening

Patient Info: Anonymized, Female | Stage III

Biomarkers: BRCA1 pathogenic variant on homologous recombination deficiency testing; germline BRCA1 pathogenic variant

At approximately 1 year after surgery, she was alive without evidence of recurrence while continuing olaparib and bevacizumab maintenance therapy.

PubMed CentralRead more →

Recurrent Malignant Ovarian Steroid Cell Tumor Treated With Multiple Therapies

Patient Info: Anonymized, Female

Biomarkers: PIK3CA, and ATM mutations; ER negative; PR negative

She experienced repeated pelvic and lung recurrences. Platinum-based treatment produced a complete PET-CT response and olaparib maintenance provided about 1 year without progression before a 5 mm lung recurrence was surgically removed.

PubMed CentralRead more →

Ovarian Cancer: Faye's Patient Story

Patient Info: Faye Belvin, Female

Faye was still receiving the trial combination and said the treatment was working and that she felt better than she had in the previous 2 years.

Recurrent Ovarian Cancer and Olaparib-Related Skin Toxicity

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Metastatic Site: peritoneum|liver

The latest chemotherapy was effective, and she was alive without signs of another recurrence at the last documented follow-up.

PubMed CentralRead more →

Stage III BRCA1 Ovarian Cancer: Patty's Patient Story

Patient Info: Patty Klein, Female | Stage III

Biomarkers: BRCA1 mutation

Patty was able to continue the olaparib plus BKM120 clinical trial as long as her tumor remained controlled. She later died.

Ovarian Cancer Relapse Causing Fluid Around the Heart

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: PAX8 positive; CK7 positive; WT1 positive; p53 positive; ER positive; PR negative; isolated PMS2 loss; MSH2 retained; MSH6 retained; MLH1 retained; two BRCA1 variants of uncertain significance

Metastatic Site: omentum|pericardium

She was alive after completing chemotherapy for the pericardial relapse and was receiving olaparib maintenance. The fluid around the heart did not recur immediately after the surgical window.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Diane's Patient Story

Patient Info: Diane Sarver, female | Stage IV

After about 7 weeks on the clinical trial, Diane's test results had normalized; she was entering her third year on treatment and planned to continue while it remained effective and tolerable.

MD AndersonRead more →